PSMA ligands developed for diagnostic and therapeutic applications in prostate cancer were originally based on 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid (DUPA) [18]. This evidence concerns the gene FOLH1 and prostate cancer.